

Financial Tear Sheet

Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

Stock Information

FCSC (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$3.10
Change (%)	0.00 (0.00%)
Volume	6,060
52 Week Low	\$2.21
Market Cap	\$23,899,435
Rolling EPS	-4.20
PE Ratio	N/A
Shares Outstanding	7,709,495

Data as of 06/22/18 4:00 p.m. ET



Recent Headlines & Events

05/31/18 - 4:05 p.m.
Fibrocell Announces Closing of \$6.0 Million Registered Direct Offering

05/29/18 - 9:20 a.m.
Fibrocell Announces \$6.0 Million Registered Direct Offering Priced At-the-Market

There are currently no events scheduled.

05/24/18 - 8:56 a.m.

Fibrocell Announces One-for-Five Reverse Stock Split

SEC Filings

Filing Date	Form
06/22/18	8-K
06/21/18	4
06/21/18	4
06/21/18	4

Corporate Governance

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	40	11.55	73.1	4,145,870
Mutual Fund	10	.21	1.4	79,822
Director and Officer	0	.00	0.0	0

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	1,653,483	29.1	0	03/31/18
Sabby Management, LLC	679,408	12.0	679,408	05/29/18
Anson Funds Management LP.	679,408	12.0	679,408	05/29/18
Heights Capital Management, Inc.	679,408	12.0	679,408	05/29/18
MSD Partners, L.P.	138,592	2.4	0	03/31/18
Point72 Asset Management, L.P.	80,000	1.4	40,000	03/31/18
The Vanguard Group, Inc.	74,729	1.3	21,273	03/31/18
Renaissance Technologies LLC	23,539	0.4	-2,220	03/31/18
Creative Planning, Inc.	22,218	0.4	3,600	03/31/18
PanAgora Asset Management Inc.	15,589	0.3	15,589	03/31/18

Data provided by Nasdaq. Minimum 15 minutes delayed.